Antimalarial drug discovery: efficacy models for compound screening.
David A Fidock;
Philip J Rosenthal;
Simon L Croft ;
Reto Brun;
Solomon Nwaka;
(2004)
Antimalarial drug discovery: efficacy models for compound screening.
Nature reviews Drug discovery, 3 (6).
pp. 509-520.
ISSN 1474-1776
DOI: 10.1038/nrd1416
Increased efforts in antimalarial drug discovery are urgently needed. The goal must be to develop safe and affordable new drugs to counter the spread of malaria parasites that are resistant to existing agents. Drug efficacy, pharmacology and toxicity are important parameters in the selection of compounds for development, yet little attempt has been made to review and standardize antimalarial drug-efficacy screens. Here, we suggest different in vitro and in vivo screens for antimalarial drug discovery and recommend a streamlined process for evaluating new compounds on the path from drug discovery to development.
Item Type | Article |
---|---|
Keywords | Plasmodium-falciparum malaria, rodent malaria, chloroquine, resistance, in-vitro, protein farnesyltransferase, sulfadoxine-, pyrimethamine, uncomplicated malaria, cysteine protease, toxoplasma-gondii, randomized trial, Animals, Antimalarials, chemistry, therapeutic use, Drug Evaluation, methods, Drug Resistance, physiology, Human, Malaria, drug therapy, epidemiology, Models, Biological, Technology, Pharmaceutical, methods |
ISI | 222187600020 |
ORCID: https://orcid.org/0000-0002-3902-8006